In short
Clinical trials are investigating Argon in people resuscitated after cardiac arrest. The main goal is to see whether Argon mixed with oxygen can help protect the brain after this emergency. These studies focus on safety and treatment effect in adults with out-of-hospital cardiac arrest.
Key points
- Clinical trials investigating Argon are focused on people resuscitated after out-of-hospital cardiac arrest. The main study is a Phase 2 interventional trial with 120 planned participants. It tests an Argon and oxygen inhalation mixture against oxygen alone. The goal is to see whether Argon can reduce neurological injury after cardiac arrest. The main measured outcome is serum neuron specific enolase, or NSE, at 48 hours.
Trial overview
The main clinical trial in the source data is the CardioPulmonary resuscitation with Argon (CPAr) trial, which is an interventional study in Phase 2. It is authorised and plans to enroll 120 people. The study is looking at whether Argon given with oxygen can help after cardiac arrest.
Who is being studied
This trial focuses on patients who have been resuscitated after out-of-hospital cardiac arrest, which means the heart stopped outside a hospital and emergency care was needed. The condition being studied is cardiac arrest, with special attention to possible brain injury after the event.
Treatment being tested
The study tests an inhaled gas mixture of Argon/Oxygen at 70% Argon and 30% oxygen. The comparison treatment is oxygen alone at 30% in inhalation gas form. The brief summary says the gas is given with an experimental ventilator that was specially modified to allow Argon/Oxygen ventilation.
Trial phase and design
The CPAr trial is a Phase 2 study. Phase 2 trials usually look more closely at whether a treatment may work in a specific group of patients while continuing safety checks, although the source data does not give extra detail beyond the phase number. This study is also described as interventional, meaning researchers actively give the study treatment and compare outcomes.
What researchers are measuring
The main outcome is the 48-hour serum neuron specific enolase (NSE) concentration. NSE is a blood marker that researchers use to help evaluate possible nerve cell or brain injury. In this study, the NSE result is being used to judge the activity of Argon in preserving neurons, which are the cells in the brain and nervous system.
Why this study matters
The trial is designed to find out whether Argon mixed with oxygen may reduce post-cardiac arrest neurological injury, meaning brain damage that can happen after the heart starts again. Because the study is being done soon after resuscitation, it targets a very serious emergency situation where protecting the brain is important. The available data show one focused study, so the current research picture is narrow but clinically important.